Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A dose escalation study of ALT-803 in patients relapsed after allogeneic hematopoietic cell transplantation

Next Previous
Trial Profile

A dose escalation study of ALT-803 in patients relapsed after allogeneic hematopoietic cell transplantation

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 08 Jan 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Inbakicept (Primary) ; Inbakicept (Primary)
  • Indications Acute myeloid leukaemia; Diffuse large B cell lymphoma; Multiple myeloma; Myelodysplastic syndromes; Precursor cell lymphoblastic leukaemia-lymphoma
  • Focus Adverse reactions; First in man; Pharmacodynamics; Pharmacokinetics; Therapeutic Use

    • Most Recent Events

    • 20 Dec 2018 According to The American Society of Hematology media release, data form this trial was published in the journal Blood.
    • 26 Dec 2017 New trial record
    • 12 Dec 2017 Results of complete study presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top